{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:52:56Z","timestamp":1791499976507,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"US Government National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.xjidi.2026.100467","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:44:22Z","timestamp":1773827062000},"page":"100467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Local IgG autoantibody profiles in hidradenitis suppurativa and their associations with disease features and anti-TNF therapy"],"prefix":"10.1016","volume":"6","author":[{"given":"Carmelo","family":"Carmona-Rivera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam J.","family":"O\u2019Neil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teja","family":"Mallela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana J.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2026.100467_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis suppurativa Foundations: part II: topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2026.100467_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav5908","article-title":"Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa","volume":"11","author":"Byrd","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.xjidi.2026.100467_bib3","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jid.2021.07.187","article-title":"Autoantibodies present in hidradenitis suppurativa correlate with disease severity and promote the release of proinflammatory cytokines in macrophages","volume":"142","author":"Carmona-Rivera","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.xjidi.2026.100467_bib4","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/exd.14092","article-title":"Beyond antibodies: B cells in Hidradenitis suppurativa: bystanders, contributors or therapeutic targets?","volume":"29","author":"Frew","year":"2020","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.xjidi.2026.100467_bib5","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.12688\/f1000research.17267.1","article-title":"A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa","volume":"7","author":"Frew","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.xjidi.2026.100467_bib6","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/exd.13978","article-title":"Contribution of fibroblasts to tunnel formation and inflammation in hidradenitis suppurativa\/ acne inversa","volume":"28","author":"Frew","year":"2019","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.xjidi.2026.100467_bib7","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139930","article-title":"Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis","volume":"5","author":"Gudjonsson","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.xjidi.2026.100467_bib8","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jaad.2015.07.052","article-title":"Hidradenitis suppurativa: epidemiology and scope of the problem","volume":"73","author":"Jemec","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2026.100467_bib9","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/bjd.17919","article-title":"Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled Pioneer trials","volume":"181","author":"Jemec","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2026.100467_bib10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xjidi.2026.100467_bib11","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jaad.2018.05.015","article-title":"Adalimumab alleviates skin pain in patients with moderate-to-severe hidradenitis suppurativa: secondary efficacy results from the Pioneer I and Pioneer II randomized controlled trials","volume":"79","author":"Kimball","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2026.100467_bib12","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/hep4.1582","article-title":"Exploratory study of autoantibody profiling in drug-induced liver injury with an autoimmune phenotype","volume":"4","author":"Lammert","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.xjidi.2026.100467_bib13","first-page":"2557","article-title":"Induction of autoantibodies during prolonged treatment with infliximab","volume":"30","author":"Louis","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.xjidi.2026.100467_bib14","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.169870","article-title":"Tertiary lymphoid structures sustain cutaneous B cell activity in hidradenitis suppurativa","volume":"9","author":"Lowe","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.xjidi.2026.100467_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139932","article-title":"Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-alpha therapy","volume":"5","author":"Lowe","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.xjidi.2026.100467_bib16","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2340\/00015555-0749","article-title":"Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents?","volume":"89","author":"Matusiak","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.xjidi.2026.100467_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2024.110764","article-title":"Differences in hidradenitis suppurativa patterns of cutaneous involvement between sexes: insights from a cross-sectional study","volume":"85","author":"Mintoff","year":"2024","journal-title":"Hum Immunol"},{"key":"10.1016\/j.xjidi.2026.100467_bib18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jid.2022.06.024","article-title":"Neutralizing anti\u2012dnase 1 and \u2012DNase 1L3 antibodies impair neutrophil extracellular traps degradation in hidradenitis suppurativa","volume":"143","author":"Oliveira","year":"2023","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.xjidi.2026.100467_bib19","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1172\/JCI136254","article-title":"Prevalence and pathogenicity of autoantibodies in patients with idiopathic CD4 lymphopenia","volume":"130","author":"Perez-Diez","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.xjidi.2026.100467_bib20","article-title":"Infliximab in hidradenitis suppurativa: a systematic review and meta-analysis","volume":"35","author":"Shih","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.xjidi.2026.100467_bib21","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated levels of tumour necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2 and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-\u03b1 and IL-1\u03b2","volume":"164","author":"van der Zee","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2026.100467_bib22","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaci.2022.02.003","article-title":"Insights into hidradenitis suppurativa","volume":"149","author":"van Straalen","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2026.100467_bib23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10067-015-3140-6","article-title":"Infliximab-induced autoantibodies: a multicenter study","volume":"35","author":"Vaz","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.xjidi.2026.100467_bib24","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1016\/j.immuni.2024.11.010","article-title":"Skin immune-mesenchymal interplay within tertiary lymphoid structures promotes autoimmune pathogenesis in hidradenitis suppurativa","volume":"57","author":"Yu","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.xjidi.2026.100467_bib25","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/jdv.16264","article-title":"Apocrine glands are bystanders in hidradenitis suppurativa and their involvement is gender specific","volume":"34","author":"Zouboulis","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2026.100467_bib26","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/jdv.16147","article-title":"Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa","volume":"34","author":"Zouboulis","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2026.100467_bib27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","article-title":"Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study","volume":"80","author":"Zouboulis","year":"2019","journal-title":"J Am Acad Dermatol"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026726000196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026726000196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:11:53Z","timestamp":1779196313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026726000196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2667026726000196"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2026.100467","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Local IgG autoantibody profiles in hidradenitis suppurativa and their associations with disease features and anti-TNF therapy","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2026.100467","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100467"}}